Synergy: BPC-157 modulates local growth factor receptors and the nitric oxide system at sites of injury, while TB-500 promotes systemic actin sequestration, angiogenesis, and immune cell migration. Together they cover local and systemic remodeling axes that complementary peptides cannot address individually.
Stack components
BPC-157
Recovery & Repair
Body Protective Compound, a gastric pentadecapeptide supporting tissue healing and gut repair.
Std dose
500 µg
Vial
5 mg + 2 mL
Conc
2500 µg/mL
Draw (100u)
20 IU
500 µg draw on 100u syringe
TB-500
Recovery & Repair
Thymosin Beta-4 fragment promoting tissue repair, flexibility, and reduced inflammation.
Std dose
2.5 mg
Vial
5 mg + 2 mL
Conc
2.5 mg/mL
Draw (100u)
100 IU
2.5 mg draw on 100u syringe
Injection timing
Both can be administered subcutaneously near the injury site (BPC-157) and at a separate systemic site (TB-500) on the same day. Stagger by 5 to 10 minutes if drawn into separate syringes.
Same syringe or separate?
Some researchers combine both peptides in the same syringe after independent reconstitution. Combined-draw stability has not been formally validated; separate administration is the more conservative choice.
Typical cycle length
4 to 8 weeks at therapeutic doses, then a 2 to 4 week washout.
Research use only. Peptide stacks compound effects and side-effect risk. Always verify Certificates of Analysis for each peptide. Consult a qualified clinician before initiating any combined protocol.
BPC-157 modulates local growth factor receptors and the nitric oxide system at sites of injury, while TB-500 promotes systemic actin sequestration, angiogenesis, and immune cell migration. Together they cover local and systemic remodeling axes that complementary peptides cannot address individually.
When should BPC-157 and TB-500 be injected?
Both can be administered subcutaneously near the injury site (BPC-157) and at a separate systemic site (TB-500) on the same day. Stagger by 5 to 10 minutes if drawn into separate syringes.
Can BPC-157 and TB-500 be drawn into the same syringe?
Some researchers combine both peptides in the same syringe after independent reconstitution. Combined-draw stability has not been formally validated; separate administration is the more conservative choice.
How long is a typical BPC-157 + TB-500 cycle?
4 to 8 weeks at therapeutic doses, then a 2 to 4 week washout.
What dose of BPC-157 pairs with TB-500?
Standard ASCEND reference dose for BPC-157: 500 µg from a 5 mg vial reconstituted with 2 mL bacteriostatic water (2500 µg/mL). Draw volume at this concentration: 0.2 mL, which is 20 IU on a 100-unit insulin syringe. Adjust to the research protocol you are following.
For research informational use only. Not medical advice. Combination protocols have not been formally validated by the FDA. Consult a qualified healthcare provider before initiating any peptide stack.